SEC filings and other documents

Double-digit growth and two major launches expected as diversification and innovation accelerate.

Diversified growth, major launches, and pipeline advances drive optimism for 2024 and beyond.

Strong revenue growth, advancing pipeline, and new launches drive optimistic outlook.

Strong revenue growth and major 2026 launches position the portfolio for continued expansion.

Record 2025 revenue and strong product growth set the stage for major launches in 2026.

FUROSCIX and AFREZZA drive growth as new trials and product enhancements expand market reach.

Phase III nebulized clofazimine trial halted for futility; DPI formulation advances to phase I.

Record Q3 revenue and SC Pharma acquisition position for accelerated growth in 2026.

Major acquisition, pipeline advances, and Afrezza relaunch set stage for accelerated growth.

ICON-1 phase 3 advances with strong safety, while robust financials back late-stage pipeline launches.

TETON-2 data, acquisition integration, and Afrezza label change drive growth and expansion.

Diversified pipeline, strategic acquisitions, and pediatric launches drive growth and stability.

Acquisition diversifies revenue, expands into cardiorenal care, and targets double-digit growth.

Q2 revenue up 6% to $77M; $500M Blackstone financing supports pipeline and Afrezza expansion.

Strong revenue growth, pipeline progress, and major financing fuel expansion in 2025.

Afrezza and pipeline advances set up strong growth, with key milestones expected in 2024–2025.

Afrezza's pediatric launch and global expansion are set to drive major growth and revenue.

Q1 revenue up 18%, non-GAAP net income up 43%, and pipeline advancing in NTM and IPF.